
A widely used diabetes drug may hold the key to preventing an aggressive form of blood cancer among those at the highest risk, new research suggests.
A study from the University of Cambridge has found that metformin, an inexpensive treatment for type 2 diabetes, could potentially prevent a form of acute myeloid leukaemia (AML) while studying the effects of the drug on mice.